메뉴 건너뛰기




Volumn 64, Issue 9, 2012, Pages 1282-1291

Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR INHIBITOR;

EID: 84865587357     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21693     Document Type: Article
Times cited : (52)

References (46)
  • 1
    • 13444266513 scopus 로고    scopus 로고
    • Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A population-based cohort study
    • Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52: 402-11.
    • (2005) Arthritis Rheum , vol.52 , pp. 402-411
    • Maradit-Kremers, H.1    Crowson, C.S.2    Nicola, P.J.3    Ballman, K.V.4    Roger, V.L.5    Jacobsen, S.J.6
  • 3
    • 67650120701 scopus 로고    scopus 로고
    • The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus
    • Full LE, Ruisanchez C, Monaco C,. The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 2009; 11: 217.
    • (2009) Arthritis Res Ther , vol.11 , pp. 217
    • Full, L.E.1    Ruisanchez, C.2    Monaco, C.3
  • 4
    • 75749092567 scopus 로고    scopus 로고
    • Heart disease and rheumatoid arthritis: Understanding the risks
    • Gabriel SE,. Heart disease and rheumatoid arthritis: understanding the risks. Ann Rheum Dis 2010; 69 Suppl: i61-4.
    • (2010) Ann Rheum Dis , vol.69 , Issue.SUPPL.
    • Gabriel, S.E.1
  • 6
    • 75749118959 scopus 로고    scopus 로고
    • EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis
    • Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 325-31.
    • (2010) Ann Rheum Dis , vol.69 , pp. 325-331
    • Peters, M.J.1    Symmons, D.P.2    McCarey, D.3    Dijkmans, B.A.4    Nicola, P.5    Kvien, T.K.6
  • 8
    • 0042887347 scopus 로고    scopus 로고
    • Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis
    • Boers M, Nurmohamed MT, Doelman CJ, Lard LR, Verhoeven AC, Voskuyl AE, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 842-5.
    • (2003) Ann Rheum Dis , vol.62 , pp. 842-845
    • Boers, M.1    Nurmohamed, M.T.2    Doelman, C.J.3    Lard, L.R.4    Verhoeven, A.C.5    Voskuyl, A.E.6
  • 9
    • 34247550873 scopus 로고    scopus 로고
    • Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: Effect of early treatment. A prospective, controlled study
    • Georgiadis AN, Papavasiliou EC, Lourida ES, Alamanos Y, Kostara C, Tselepis AD, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment. A prospective, controlled study. Arthritis Res Ther 2006; 8: R82.
    • (2006) Arthritis Res Ther , vol.8
    • Georgiadis, A.N.1    Papavasiliou, E.C.2    Lourida, E.S.3    Alamanos, Y.4    Kostara, C.5    Tselepis, A.D.6
  • 10
    • 64949111191 scopus 로고    scopus 로고
    • Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: A challenge to conventional cardiovascular risk actions
    • Choy E, Sattar N,. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009; 68: 460-9.
    • (2009) Ann Rheum Dis , vol.68 , pp. 460-469
    • Choy, E.1    Sattar, N.2
  • 11
    • 79951517914 scopus 로고    scopus 로고
    • Lipid paradox in rheumatoid arthritis: The impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease
    • Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011; 70: 482-7.
    • (2011) Ann Rheum Dis , vol.70 , pp. 482-487
    • Myasoedova, E.1    Crowson, C.S.2    Kremers, H.M.3    Roger, V.L.4    Fitz-Gibbon, P.D.5    Therneau, T.M.6
  • 12
    • 33846866318 scopus 로고    scopus 로고
    • Lipids and inflammation: Serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis
    • Van Halm VP, Nielen MM, Nurmohamed MT, van Schaardenburg D, Reesink HW, Voskuyl AE, et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007; 66: 184-8.
    • (2007) Ann Rheum Dis , vol.66 , pp. 184-188
    • Van Halm, V.P.1    Nielen, M.M.2    Nurmohamed, M.T.3    Van Schaardenburg, D.4    Reesink, H.W.5    Voskuyl, A.E.6
  • 13
    • 77953382568 scopus 로고    scopus 로고
    • Intima-media thickness evolution after treatment with infliximab in patients with rheumatoid arthritis
    • Di Micco P, Ferrazzi P, Libre L, Mendolicchio L, Quaglia I, De Marco M, et al. Intima-media thickness evolution after treatment with infliximab in patients with rheumatoid arthritis. Int J Gen Med 2009; 2: 141-4.
    • (2009) Int J Gen Med , vol.2 , pp. 141-144
    • Di Micco, P.1    Ferrazzi, P.2    Libre, L.3    Mendolicchio, L.4    Quaglia, I.5    De Marco, M.6
  • 14
    • 0037029418 scopus 로고    scopus 로고
    • Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study
    • Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F,. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-7.
    • (2002) Lancet , vol.359 , pp. 1173-1177
    • Choi, H.K.1    Hernan, M.A.2    Seeger, J.D.3    Robins, J.M.4    Wolfe, F.5
  • 15
    • 34447333111 scopus 로고    scopus 로고
    • Response to anti-tumour necrosis factor α blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis
    • Del Porto F, Lagana B, Lai S, Nofroni I, Tinti F, Vitale M, et al. Response to anti-tumour necrosis factor α blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 1111-5.
    • (2007) Rheumatology (Oxford) , vol.46 , pp. 1111-1115
    • Del Porto, F.1    Lagana, B.2    Lai, S.3    Nofroni, I.4    Tinti, F.5    Vitale, M.6
  • 17
    • 67651207993 scopus 로고    scopus 로고
    • Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis
    • Wijbrandts CA, van Leuven SI, Boom HD, Gerlag DM, Stroes EG, Kastelein JJ, et al. Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1316-21.
    • (2009) Ann Rheum Dis , vol.68 , pp. 1316-1321
    • Wijbrandts, C.A.1    Van Leuven, S.I.2    Boom, H.D.3    Gerlag, D.M.4    Stroes, E.G.5    Kastelein, J.J.6
  • 18
    • 34848898513 scopus 로고    scopus 로고
    • Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register
    • British Society for Rheumatology Biologics Register Control Centre Consortium, et al, on behalf of the British Society for Rheumatology Biologics Register
    • Dixon WG, Watson KD, Lunt M, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, et al, on behalf of the British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56: 2905-12.
    • (2007) Arthritis Rheum , vol.56 , pp. 2905-2912
    • Dixon, W.G.1    Watson, K.D.2    Lunt, M.3    Hyrich, K.L.4    Silman, A.J.5
  • 19
    • 40549134937 scopus 로고    scopus 로고
    • Does tumor necrosis factor α inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
    • Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, et al. Does tumor necrosis factor α inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 2008; 58: 667-77.
    • (2008) Arthritis Rheum , vol.58 , pp. 667-677
    • Listing, J.1    Strangfeld, A.2    Kekow, J.3    Schneider, M.4    Kapelle, A.5    Wassenberg, S.6
  • 20
    • 57349141486 scopus 로고    scopus 로고
    • Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages
    • Reiss AB, Carsons SE, Anwar K, Rao S, Edelman SD, Zhang H, et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum 2008; 58: 3675-83.
    • (2008) Arthritis Rheum , vol.58 , pp. 3675-3683
    • Reiss, A.B.1    Carsons, S.E.2    Anwar, K.3    Rao, S.4    Edelman, S.D.5    Zhang, H.6
  • 21
    • 77956190766 scopus 로고    scopus 로고
    • A systematic review of the effect of TNF-α antagonists on lipid profiles in patients with rheumatoid arthritis
    • Pollono EN, Lopez-Olivo MA, Lopez JA, Suarez-Almazor ME,. A systematic review of the effect of TNF-α antagonists on lipid profiles in patients with rheumatoid arthritis. Clin Rheumatol 2010; 29: 947-55.
    • (2010) Clin Rheumatol , vol.29 , pp. 947-955
    • Pollono, E.N.1    Lopez-Olivo, M.A.2    Lopez, J.A.3    Suarez-Almazor, M.E.4
  • 22
    • 0037126526 scopus 로고    scopus 로고
    • Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): Final report
    • Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
    • Third Report of the National Cholesterol Education Program (NCEP) Expert Panel. Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): final report. Circulation 2002; 106: 3143-421.
    • (2002) Circulation , vol.106 , pp. 3143-3421
  • 23
    • 33646492303 scopus 로고    scopus 로고
    • Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy
    • Dahlqvist SR, Engstrand S, Berglin E, Johnson O,. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol 2006; 35: 107-11.
    • (2006) Scand J Rheumatol , vol.35 , pp. 107-111
    • Dahlqvist, S.R.1    Engstrand, S.2    Berglin, E.3    Johnson, O.4
  • 24
    • 38449102126 scopus 로고    scopus 로고
    • Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritis
    • [letter]
    • Seriolo B, Paolino S, Ferrone C, Cutolo M,. Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritis [letter]. Clin Rheumatol 2007; 26: 1799-800.
    • (2007) Clin Rheumatol , vol.26 , pp. 1799-1800
    • Seriolo, B.1    Paolino, S.2    Ferrone, C.3    Cutolo, M.4
  • 25
    • 58249090777 scopus 로고    scopus 로고
    • Comments on the original article by Soubrier et al: "Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis"
    • [letter].:; author reply 118
    • Seriolo B, Paoliono S, Ferrone C, Cutolo M,. Comments on the original article by Soubrier, et al. "effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis" [letter]. Joint Bone Spine 2009; 76: 117-8; author reply 118.
    • (2009) Joint Bone Spine , vol.76 , pp. 117-118
    • Seriolo, B.1    Paoliono, S.2    Ferrone, C.3    Cutolo, M.4
  • 26
    • 13244252637 scopus 로고    scopus 로고
    • Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis
    • Popa C, Netea MG, Radstake T, van der Meer JW, Stalenhoef AF, van Riel PL, et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005; 64: 303-5.
    • (2005) Ann Rheum Dis , vol.64 , pp. 303-305
    • Popa, C.1    Netea, M.G.2    Radstake, T.3    Van Der Meer, J.W.4    Stalenhoef, A.F.5    Van Riel, P.L.6
  • 27
    • 23644442893 scopus 로고    scopus 로고
    • Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family
    • Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005; 5: 1731-40.
    • (2005) Int Immunopharmacol , vol.5 , pp. 1731-1740
    • Mihara, M.1    Kasutani, K.2    Okazaki, M.3    Nakamura, A.4    Kawai, S.5    Sugimoto, M.6
  • 28
    • 75749151357 scopus 로고    scopus 로고
    • Lipid and inflammatory biomarker profiles in patients receiving tocilizumab for rheumatoid arthritis: Analysis of five phase 3 clinical trials
    • [abstract]
    • Genovese MC, Smolen JS, Emery P, Jones G, Lee JS, Alecock E, et al. Lipid and inflammatory biomarker profiles in patients receiving tocilizumab for rheumatoid arthritis: analysis of five phase 3 clinical trials [abstract]. Arthritis Rheum 2008; 58 Suppl: S531-2.
    • (2008) Arthritis Rheum , vol.58 , Issue.SUPPL.
    • Genovese, M.C.1    Smolen, J.S.2    Emery, P.3    Jones, G.4    Lee, J.S.5    Alecock, E.6
  • 29
    • 33749363027 scopus 로고    scopus 로고
    • Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
    • for the CHARISMA Study Group
    • Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al, for the CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54: 2817-29.
    • (2006) Arthritis Rheum , vol.54 , pp. 2817-2829
    • Maini, R.N.1    Taylor, P.C.2    Szechinski, J.3    Pavelka, K.4    Broll, J.5    Balint, G.6
  • 30
    • 34447300492 scopus 로고    scopus 로고
    • Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
    • Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66: 1162-7.
    • (2007) Ann Rheum Dis , vol.66 , pp. 1162-1167
    • Nishimoto, N.1    Hashimoto, J.2    Miyasaka, N.3    Yamamoto, K.4    Kawai, S.5    Takeuchi, T.6
  • 31
    • 77958161240 scopus 로고    scopus 로고
    • Long-term safety and tolerability of tocilizumab treatment in patients with rheumatoid arthritis and a mean treatment duration of 2.4 years
    • [abstract]
    • Van Vollenhoven RF, Siri D, Furie R, Krasnow J, Alecock E, Alten R,. Long-term safety and tolerability of tocilizumab treatment in patients with rheumatoid arthritis and a mean treatment duration of 2.4 years [abstract]. Arthritis Rheum 2009; 60 Suppl: S731.
    • (2009) Arthritis Rheum , vol.60 , Issue.SUPPL.
    • Van Vollenhoven, R.F.1    Siri, D.2    Furie, R.3    Krasnow, J.4    Alecock, E.5    Alten, R.6
  • 32
    • 79952899353 scopus 로고    scopus 로고
    • Safety of tocilizumab in patients with rheumatoid arthritis: Analysis of median of 2.6 years of treatment in long-tern extension studies
    • [abstract]
    • Van Vollenhoven R, Scali J, Curtis J, Krasnow J, Vernon E, Alten R,. Safety of tocilizumab in patients with rheumatoid arthritis: analysis of median of 2.6 years of treatment in long-tern extension studies [abstract]. Ann Rheum Dis 2010; 69 Suppl: 544.
    • (2010) Ann Rheum Dis , vol.69 , Issue.SUPPL. , pp. 544
    • Van Vollenhoven, R.1    Scali, J.2    Curtis, J.3    Krasnow, J.4    Vernon, E.5    Alten, R.6
  • 33
    • 70349780621 scopus 로고    scopus 로고
    • Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis
    • Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D, et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 2009; 60: 2870-9.
    • (2009) Arthritis Rheum , vol.60 , pp. 2870-2879
    • Charles-Schoeman, C.1    Watanabe, J.2    Lee, Y.Y.3    Furst, D.E.4    Amjadi, S.5    Elashoff, D.6
  • 34
    • 56349154816 scopus 로고    scopus 로고
    • Altered lipoprotein metabolism in chronic inflammatory states: Proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis
    • Hahn BH, Grossman J, Ansell BJ, Skaggs BJ, McMahon M,. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2008; 10: 213.
    • (2008) Arthritis Res Ther , vol.10 , pp. 213
    • Hahn, B.H.1    Grossman, J.2    Ansell, B.J.3    Skaggs, B.J.4    McMahon, M.5
  • 35
    • 84925548040 scopus 로고    scopus 로고
    • Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: Acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis
    • Dessein PH, Stanwix AE, Joffe BI,. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 2002; 4: R5.
    • (2002) Arthritis Res , vol.4
    • Dessein, P.H.1    Stanwix, A.E.2    Joffe, B.I.3
  • 36
    • 67649833745 scopus 로고    scopus 로고
    • Rheumatoid arthritis: Model of systemic inflammation driving atherosclerosis
    • Ku IA, Imboden JB, Hsue PY, Ganz P,. Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis. Circ J 2009; 73: 977-85.
    • (2009) Circ J , vol.73 , pp. 977-985
    • Ku, I.A.1    Imboden, J.B.2    Hsue, P.Y.3    Ganz, P.4
  • 38
    • 37749039808 scopus 로고    scopus 로고
    • Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?
    • Gonzalez A, Maradit Kremers H, Crowson CS, Ballman KV, Roger VL, Jacobsen SJ, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis 2008; 67: 64-9.
    • (2008) Ann Rheum Dis , vol.67 , pp. 64-69
    • Gonzalez, A.1    Maradit Kremers, H.2    Crowson, C.S.3    Ballman, K.V.4    Roger, V.L.5    Jacobsen, S.J.6
  • 39
    • 43049156331 scopus 로고    scopus 로고
    • Cardiovascular risk in rheumatoid arthritis: Effects of anti-TNF drugs
    • Avouac J, Allanore Y,. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opin Pharmacother 2008; 9: 1121-8.
    • (2008) Expert Opin Pharmacother , vol.9 , pp. 1121-1128
    • Avouac, J.1    Allanore, Y.2
  • 40
    • 55349118821 scopus 로고    scopus 로고
    • Mortality in rheumatoid arthritis: 2008 update
    • Sokka T, Abelson B, Pincus T,. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008; 26 Suppl: S35-61.
    • (2008) Clin Exp Rheumatol , vol.26 , Issue.SUPPL.
    • Sokka, T.1    Abelson, B.2    Pincus, T.3
  • 41
    • 77956503955 scopus 로고    scopus 로고
    • Explaining the cardiovascular risk associated with rheumatoid arthritis: Traditional risk factors versus markers of rheumatoid arthritis severity
    • Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010; 69: 1920-5.
    • (2010) Ann Rheum Dis , vol.69 , pp. 1920-1925
    • Solomon, D.H.1    Kremer, J.2    Curtis, J.R.3    Hochberg, M.C.4    Reed, G.5    Tsao, P.6
  • 42
    • 34848912752 scopus 로고    scopus 로고
    • Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis
    • Popa C, van den Hoogen FH, Radstake TR, Netea MG, Eijsbouts AE, den Heijer M, et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1503-7.
    • (2007) Ann Rheum Dis , vol.66 , pp. 1503-1507
    • Popa, C.1    Van Den Hoogen, F.H.2    Radstake, T.R.3    Netea, M.G.4    Eijsbouts, A.E.5    Den Heijer, M.6
  • 43
    • 33646445868 scopus 로고    scopus 로고
    • Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis
    • Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA,. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2006; 33: 921-3.
    • (2006) J Rheumatol , vol.33 , pp. 921-923
    • Kiortsis, D.N.1    Mavridis, A.K.2    Filippatos, T.D.3    Vasakos, S.4    Nikas, S.N.5    Drosos, A.A.6
  • 44
    • 34347219723 scopus 로고    scopus 로고
    • Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis
    • Peters MJ, Vis M, van Halm VP, Wolbink GJ, Voskuyl AE, Lems WF, et al. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 958-61.
    • (2007) Ann Rheum Dis , vol.66 , pp. 958-961
    • Peters, M.J.1    Vis, M.2    Van Halm, V.P.3    Wolbink, G.J.4    Voskuyl, A.E.5    Lems, W.F.6
  • 45
    • 0023092594 scopus 로고
    • A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
    • Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
    • (1987) J Chronic Dis , vol.40 , pp. 373-383
    • Charlson, M.E.1    Pompei, P.2    Ales, K.L.3    MacKenzie, C.R.4
  • 46
    • 0026548664 scopus 로고
    • A chronic disease score from automated pharmacy data
    • Von Korff M, Wagner EH, Saunders K,. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992; 45: 197-203.
    • (1992) J Clin Epidemiol , vol.45 , pp. 197-203
    • Von Korff, M.1    Wagner, E.H.2    Saunders, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.